CUSIP: 13739U104
Q1 2018 13F Holders as of 31 Mar 2018
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
4,772,097
-
Share change
-
-202,891
-
Total reported value
-
$7,875,000
-
Price per share
-
$1.65
-
Number of holders
-
25
-
Value change
-
-$352,264
-
Number of buys
-
9
-
Number of sells
-
11
Quarterly Holders Quick Answers
What is CUSIP 13739U104?
CUSIP 13739U104 identifies CGIX - CANCER GENETICS INC - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q2 2018
-
Previous quarter:
Q4 2017
Recent filing periods for CUSIP 13739U104:
Institutional Holders of CANCER GENETICS INC - COM (CGIX) as of Q1 2018
As of 31 Mar 2018,
CANCER GENETICS INC - COM (CGIX) was held by
25 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
4,772,097 shares.
The largest 10 holders included
Stonepine Capital Management, LLC, PERKINS CAPITAL MANAGEMENT INC, VANGUARD GROUP INC, RENAISSANCE TECHNOLOGIES LLC, GRANAHAN INVESTMENT MANAGEMENT INC/MA, Fairbanks Capital Management, Inc., GEODE CAPITAL MANAGEMENT, LLC, DIKER MANAGEMENT LLC, UBS Group AG, and WEDBUSH SECURITIES INC.
This page lists
25
institutional shareholders reporting positions in this security
for the Q1 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.